Skip to content
2000
Volume 28, Issue 12
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the novel coronavirus responsible for the current global pandemic, which first emerged in December 2019. This coronavirus has affected 217 countries worldwide, most of which have enacted non-remedial preventive measures, such as nationwide lockdowns, work from home, travel bans, and social isolation. Pharmacists, doctors, nurses, technologists, and other healthcare professionals have played pivotal roles during this pandemic. Unfortunately, confirmed drugs have not been identified for the treatment of patients with coronavirus disease 2019 (COVID-19) caused by SARSCoV2; however, favipiravir and remdesivir have been reported as promising antiviral drugs. Some vaccines have already been developed, and vaccination is ongoing globally. Various nanotechnologies are currently being developed in many countries for preventing SARS-CoV-2 spread and treating COVID-19 infections. In this article, we present an overview of the COVID-19 pandemic situation and discuss nanotechnology-based approaches and investigational therapeutics for COVID-19.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612827666210701150315
2022-04-01
2024-12-27
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612827666210701150315
Loading

  • Article Type:
    Review Article
Keyword(s): antiviral drugs; COVID-19; immunomodulation; nanotechnology; SARS-COV-2; vaccines
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test